Results 171 to 180 of about 60,295 (253)

Considerations for the clinical use of teplizumab in stage 2 Type 1 diabetes: A Consensus Statement from the British Society of Paediatric Endocrinology and Diabetes (BSPED) and the Association of British Clinical Diabetologists (ABCD)

Diabetic Medicine, Volume 43, Issue 7, July 2026.
Abstract Introduction In 2025, the Medicines and Healthcare products Regulatory Agency (MHRA) approved the use of teplizumab (a monoclonal anti‐CD3 antibody) to delay progression from Stage 2 to Stage 3 Type 1 diabetes in the UK. Methods To address the need for clear guidance on managing patients eligible for teplizumab therapy, the British Society of ...
Renuka P. Dias, M. Loredana Marcovecchio, Ruben H. Willemsen, Fiona Campbell, Ahmad Ashour, Philip Newland‐Jones, Jennifer Cooper, Parth Narendran, Neil P. Wright   +8 more
wiley   +1 more source

Normal tissue complication probability modeling of severe radiation-induced lymphopenia using blood dose for lung cancer patients treated with IMRT and IMPT. [PDF]

Front Immunol
Wang S, Dai T, Fan X, Li W, Huang W, Wang R, Yin Y.   +6 more
europepmc   +1 more source

Elranatamab in Relapsed/Refractory Multiple Myeloma: Mechanisms, Clinical Evidence, and Emerging Perspectives

European Journal of Haematology, Volume 117, Issue 1, Page 42-54, July 2026.
ABSTRACT Relapsed and refractory multiple myeloma (RRMM) remains associated with poor outcomes, particularly in patients exposed or refractory to proteasome inhibitors, immunomodulatory agents, and anti‐CD38 monoclonal antibodies. Targeting B‐cell maturation antigen (BCMA) has emerged as an effective therapeutic strategy, prompting the development of ...
Maria Eugenia Alvaro, Enrica Antonia Martino, Santino Caserta, Mamdouh Skafi, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

Maintenance therapy for metastatic non-squamous non-small cell lung cancer: efficacy and biomarker analysis of pemetrexed discontinuation. [PDF]

Transl Lung Cancer Res
Lin Y, Gong K, Wu J, Wei C, Yu B, Hu Z, Zhang Y, Wu Z, Zhao X, Yu H, Wu X, Wang J, Yang X, Wang H.   +13 more
europepmc   +1 more source

Ph‐Negative Acute Lymphoblastic Leukemia in the Older Adults: Biology, Therapeutic Strategies and Unmet Needs

European Journal of Haematology, Volume 117, Issue 1, Page 24-41, July 2026.
ABSTRACT Acute lymphoblastic leukaemia (ALL) in older adults represents a growing clinical challenge, driven by an ageing population, adverse disease biology, and reduced tolerance to intensive chemotherapy. Although pediatric‐inspired regimens have improved outcomes in younger adults with Philadelphia chromosome (Ph)‐negative ALL, survival in older ...
Antonella Bruzzese, Ernesto Vigna, Enrica Antonia Martino, Santino Caserta, Francesco Mendicino, Maria Eugenia Alvaro, Caterina Labanca, Eugenio Lucia, Virginia Olivito, Marco Fiorillo, Nicola Amodio, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

Case Report: Transient severe T cell lymphopenia in a patient with Cornelia de Lange Syndrome captured by TREC screening. [PDF]

Front Immunol
Retif H, Rolhfs Rivera D, Upadia J, Wysocki C, Abreo A, Wall LA.   +5 more
europepmc   +1 more source

Pharmacological Treatment of Cerebellar Ataxia in Pediatric Ataxia‐Telangiectasia: A Systematic Review

European Journal of Neurology, Volume 33, Issue 7, July 2026.
ABSTRACT Introduction Ataxia‐telangiectasia (AT) is characterized by progressive cerebellar ataxia, oculomotor apraxia, immunodeficiency, and increased cancer susceptibility. No disease‐modifying treatment is available. This systematic review aimed to evaluate the efficacy and safety of pharmacological interventions for ataxia in pediatric AT. Method A
Fabiola Panvino, Roberto Paparella, Giorgia Urciuolo, Serena Galosi, Carlotta Spagnoli, Vincenzo Leuzzi, Francesco Pisani   +6 more
wiley   +1 more source

Transfusion‐Associated Graft‐Versus‐Host Disease Risk and Transfusion Requirements After Cladribine in Multiple Sclerosis: Time to Revise Irradiation Policy?

European Journal of Neurology, Volume 33, Issue 7, July 2026.
ABSTRACT Background Irradiation of cellular blood components prevents transfusion‐associated graft‐versus‐host disease (TA‐GVHD). UK and Spanish guidance recommend lifelong irradiation for all patients treated with purine analogues, including cladribine, irrespective of indication or dose.
Klaus Schmierer, Frederick Chen, David Paling   +2 more
wiley   +1 more source

Pneumocystis jirovecii pneumonia prophylaxis in patients with glioma receiving concurrent chemoradiation: a systematic review and meta-analysis. [PDF]

EClinicalMedicine
Jia JL, Alshamsan B, Beltran-Bless A, MacRae M, Rose F, Leigh J, Chowdhury D, Fazzari F, Lo V, Lee SF, Ng TL.   +10 more
europepmc   +1 more source

Hypertransaminasemia Is a Marker of Severity in Children Hospitalized for Influenza

Influenza and Other Respiratory Viruses, Volume 20, Issue 7, July 2026.
ABSTRACT Purpose Elevated transaminases have been associated with increased severity in adult influenza cases, but data in the pediatric population are limited. This study aims to evaluate the prevalence, clinical characteristics and prognostic value of elevated transaminases in children hospitalized for influenza.
Marco Poeta, Cristina Moracas, Elisabetta Venturini, Sofia Sgubbi, Maria Sole Valentino, Laura Folgori, Laura Petrarca, Claudio Cafagno, Marco Maglione, Anna Cascone, Claudia Colomba, Alice Romero, Fabio Midulla, Giuseppe Indolfi, Vania Giacomet, Amelia Licari, Luisa Galli, Alfredo Guarino   +17 more
wiley   +1 more source